<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immunosuppressive agents used in heart transplantation&lt;SUP&gt;[1]&lt;/SUP&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immunosuppressive agents used in heart transplantation<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Immunosuppressive agents used in heart transplantation<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Dosing</td> <td class="subtitle1">Target levels</td> <td class="subtitle1">Major toxicities</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Calcineurin inhibitors</td> </tr> <tr> <td class="indent1">Cyclosporine</td> <td>4 to 8 mg/kg/day in 2 divided doses, titrated to keep target 12-hour trough levels</td> <td> <p><strong>0 to 6 weeks:</strong></p> <p>275 to 375 ng/mL</p> <p><strong>6 to 12 weeks:</strong></p> <p>200 to 350 ng/mL</p> <p><strong>3 to 6 months:</strong></p> <p>150 to 300 ng/mL</p> <p><strong>&gt;6 months:</strong></p> <p>150 to 250 ng/mL</p> </td> <td> <p>Renal insufficiency</p> <p>Hypertension</p> <p>Dyslipidemia</p> <p>Hypokalemia and hypomagnesemia</p> <p>Hyperuricemia</p> <p>Neurotoxicity (encephalopathy, seizures, tremors, neuropathy)</p> <p>Gingival hyperplasia</p> <p>Hirsutism</p> </td> </tr> <tr> <td class="indent1">Tacrolimus</td> <td>0.05 to 0.1 mg/kg/day in 2 divided doses, titrated to keep target 12-hour trough levels</td> <td> <p><strong>0 to 2 months:</strong></p> <p>10 to 15 ng/mL</p> <p><strong>3 to 6 months:</strong></p> <p>8 to 12 ng/mL</p> <p><strong>&gt;6 months:</strong></p> <p>5 to 10 ng/mL</p> </td> <td> <p>Renal dysfunction</p> <p>Hypertension</p> <p>Hyperglycemia and diabetes mellitus</p> <p>Dyslipidemia</p> <p>Hyperkalemia</p> <p>Hypomagnesemia</p> <p>Neurotoxicity (tremors, headaches)</p> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Cell cycle agents</td> </tr> <tr> <td class="indent1">Azathioprine</td> <td>1.5 to 3.0 mg/kg/day, titrated to keep WBC at or slightly above 3000/mm<sup>3</sup></td> <td>None</td> <td> <p>Bone marrow suppression</p> <p>Hepatitis (rare)</p> <p>Pancreatitis</p> <p>Malignancy</p> </td> </tr> <tr> <td class="indent1">Mycophenolate mofetil</td> <td>1000 to 1500 mg/day twice daily</td> <td>Mycophenolic acid (MPA): 2 to 5 mcg/mL</td> <td> <p>Gastrointestinal disturbances (nausea, gastritis, and diarrhea)</p> <p>Leukopenia</p> </td> </tr> <tr> <td class="indent1">Mycophenolate sodium</td> <td>720 to 1080 twice daily</td> <td>None</td> <td> <p>Fewer gastrointestinal disturbances compared with mycophenolate mofetil</p> Leukopenia</td> </tr> <tr> <td class="subtitle2_left" colspan="4">Proliferation signal inhibitors</td> </tr> <tr> <td class="indent1">Sirolimus</td> <td>1 to 3 mg/day, titrated to keep therapeutic 24-hour trough levels</td> <td> <p>4 to 12 ng/mL when used in combination with a CNI</p> <p> </p> <p>8 to 14 ng/mL when used as part of a CNI-free regimen</p> <p> </p> <p>Target ranges vary depending upon the assay used, so clinicians should use the reference range for the assay used at their institutions. </p> </td> <td> <p>Oral ulcerations</p> <p>Hypercholesterolemia and hypertriglyceridemia</p> <p>Poor wound healing</p> <p>Lower extremity edema</p> <p>Pulmonary toxicities (pneumonitis, alveolar hemorrhage)</p> <p>Leukopenia, anemia, and thrombocytopenia</p> <p>Potentiation of CNI nephrotoxicity</p> </td> </tr> <tr> <td class="indent1">Everolimus</td> <td>1.5 mg/day in 2 divided doses </td> <td> <p>3 to 8 ng/mL when used in combination with a CNI</p> <p>6 to 10 ng/mL when used as part of a CNI-free regimen</p> </td> <td>Similar to sirolimus </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Corticosteroids</td> </tr> <tr> <td class="indent1">Prednisone</td> <td> <p>1 mg/kg/day in 2 divided doses, tapered to 0.05 mg/kg/day by 6 to 12 months</p> <p> </p> <p>(Prednisone is typically administered after 24 hours of treatment with methylprednisolone immediately following transplantation.)</p> </td> <td>None</td> <td> <p>Weight gain</p> <p>Hypertension</p> <p>Hyperlipidemia</p> <p>Osteopenia</p> <p>Hyperglycemia</p> <p>Poor wound healing</p> <p>Salt and water retention</p> <p>Proximal myopathy</p> <p>Cataracts</p> <p>Peptic ulcer disease</p> <p>Growth retardation</p> </td> </tr> </tbody></table></div><div class="graphic_footnotes">WBC: white blood cell; CNI: calcineurin inhibitor.</div><div class="graphic_reference">Updated from:<br/><ol>
<li>Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29:914.</li></ol>Reproduced with permission and updated from: Pham MX, Chen JM, Berry GJ, Rose EA, Schroeder JS. Surgical Treatment of Heart Failure, Cardiac Transplantation, and Mechanical Ventricular Support. In: Hurst's The Heart, 12<sup>th</sup> ed, V, Fuster R, O'Rourke R, Walsh P, Poole-Wilson (eds). McGraw-Hill, New York 2007. Copyright © 2007 McGraw-Hill Companies Inc.</div><div id="graphicVersion">Graphic 50962 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
